Request availability and a quotation for your required quantity and destination.
| Product | Eflornithine 13.9% - Eflora Cream |
|---|---|
| Categories | Skin Care |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Related educational guide: Eflornithine cream: results and safety. General information only; follow clinician or veterinarian instructions for the exact product.
Product category: Skin Care
Active ingredient: Eflornithine 13.9% (confirm manufacturer formulation)
Dosage form: Topical facial cream
Prescription status: Confirm local requirements
Eflora is listed as an eflornithine 13.9% cream for managing unwanted facial hair. Clinical information below draws on labeling for the reference eflornithine product Vaniqa; product-specific equivalence, ingredients and instructions must be confirmed from the manufacturer.
Eflornithine reduces the rate of unwanted facial-hair growth in women. It is not a depilatory and does not treat the underlying cause of increased hair growth, such as an endocrine condition.
Eflornithine inhibits ornithine decarboxylase, an enzyme involved in hair follicle activity. Visible results generally require regular use and may take several weeks.
Reference labeling describes a thin layer to the affected facial and under-chin areas twice daily at least eight hours apart; users should avoid washing the area for four hours. The actual supplied product’s instructions take priority. Do not use near eyes, on broken skin, or as a substitute for hair-removal techniques.
Facial irritation, temporary stinging, burning, acne-like bumps, rash and folliculitis may occur. Stop and seek help for suspected serious allergy. Pregnancy, breastfeeding, unusual sudden facial hair growth and associated hormonal symptoms warrant medical advice.
Explore the Skin Care catalogue and tretinoin gel information for other skin concerns; these are not treatments for unwanted facial hair and should not be substituted.
DailyMed: eflornithine 13.9% (Vaniqa) clinical labeling
Eflornithine 13.9% cream slows unwanted facial-hair growth in women. It does not permanently remove hair.
Improvement was observed within about 4–8 weeks in clinical studies, though results vary.
No. Facial-hair growth can return after treatment is stopped.
Hair removal may still be needed. Follow the product leaflet; the reference cream was applied at least five minutes after hair removal.
Reference labeling includes the face and adjacent under-chin area in women.
It may slow unwanted hair growth but does not treat underlying hormonal conditions such as PCOS. Medical evaluation may be needed.
Reference labeling permits cosmetics and sunscreen after the cream has dried.
Stinging, burning, rash, redness, acne or folliculitis can occur.
Safety data are limited; a clinician should weigh risks and generally consider other hair-removal approaches during pregnancy.
Hair growth may gradually return toward pretreatment levels; the reference trials reported return within about eight weeks.
Cureiva Healthcare responds to product enquiries subject to verified packaging, availability and destination-country requirements. Educational content based on reference labeling; independent clinician approval has not been claimed. Updated October 2026.